{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T20:56:44Z","timestamp":1760648204505,"version":"3.44.0"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Mavacamten has been demonstrated to be effective in the treatment of hypertrophic obstructive cardiomyopathy (HOCM). However, its hemodynamic impact and extracardiac effects require further characterization.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>We report a case of a 68-year-old female diagnosed with severe HOCM who experienced transient hypertension (165\/105\u2005mmHg) and myalgia four weeks after mavacamten initiation. Despite a significant reduction in LVOT obstruction (from 64\u2005mmHg\u201318\u2005mmHg) and an increase in LVEF to 78%, the patient exhibited a transient hypertensive response that resolved spontaneously within two weeks without intervention. Myalgia was present without corresponding elevations in serum creatine kinase.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This case highlights a previously unrecognized transient hypertensive phase associated with myosin inhibition, potentially related to ventriculo-arterial decoupling and peripheral vascular adaptation. Additionally, the dissociation between myalgia and CK elevation suggests alternative skeletal muscle involvement mechanisms. Close blood pressure monitoring and further investigation into the extracardiac effects of mavacamten are warranted.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2025.1578356","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T05:25:08Z","timestamp":1757481908000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Transient hypertension and myalgia following mavacamten therapy in a patient with hypertrophic obstructive cardiomyopathy"],"prefix":"10.3389","volume":"12","author":[{"given":"Mengling","family":"Peng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jchf.2023.07.030","article-title":"Mavacamten for obstructive hypertrophic cardiomyopathy with or without hypertension: post-hoc analysis of the EXPLORER-HCM trial","volume":"12","author":"Wang","year":"2024","journal-title":"JACC Heart Fail"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Affcamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"ytae450","DOI":"10.1093\/ehjcr\/ytae450","article-title":"Accelerated hypertension following mavacamten introduction in severe obstructive hypertrophic cardiomyopathy with hypertension: a case report","volume":"8","author":"Maurizi","year":"2024","journal-title":"Eur Heart J Case Rep"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e028479","DOI":"10.1161\/JAHA.122.028479","article-title":"Noninvasive hemodynamic evaluation following TAVI for severe aortic stenosis","volume":"12","author":"Grinberg","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"B5","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.jcin.2012.12.124","article-title":"Post-procedural hypertension following transcatheter aortic valve implantation: incidence and clinical significance","volume":"6","author":"Perlman","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e010994","DOI":"10.1136\/heartasia-2017-010994","article-title":"The development or worsening of hypertension after transcatheter aortic valve replacement (TAVR) improves short-term and long-term patient outcomes","volume":"10","author":"Klinkhammer","year":"2018","journal-title":"Heart Asia"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s10554-019-01563-3","article-title":"Myocardial adaptation after surgical therapy differs for aortic valve stenosis and hypertrophic obstructive cardiomyopathy","volume":"35","author":"Parbhudayal","year":"2019","journal-title":"Int J Cardiovasc Imaging"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","article-title":"Statin-associated myopathy","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"key":"B9","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1126\/science.aad3456","article-title":"A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice","volume":"351","author":"Green","year":"2016","journal-title":"Science"},{"key":"B10","doi-asserted-by":"publisher","first-page":"16571","DOI":"10.1074\/jbc.M117.776815","article-title":"A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle","volume":"292","author":"Kawas","year":"2017","journal-title":"J Biol Chem"},{"key":"B11","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s40256-024-00672-2","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) for mavacamten","volume":"24","author":"Yukselen","year":"2024","journal-title":"Am J Cardiovasc Drugs"},{"key":"B12","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.acvd.2024.12.013","article-title":"Characterization of left atrial strain in left ventricular hypertrophy: a study of fabry disease, sarcomeric hypertrophic cardiomyopathy and cardiac amyloidosis","volume":"118","author":"Massie","year":"2025","journal-title":"Arch Cardiovasc Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12947-025-00339-1","article-title":"Determinants of left atrial reservoir strain and diagnostic potential for cardiac amyloidosis in pathological left ventricular hypertrophy","volume":"23","author":"Inoue","year":"2025","journal-title":"Cardiovasc Ultrasound"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1111\/jce.14526","article-title":"The arrhythmogenic right ventricular cardiomyopathy in comparison to the athletic heart","volume":"31","author":"Mascia","year":"2020","journal-title":"J Cardiovasc Electrophysiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.medcli.2023.10.006","article-title":"Clinical differences between transthyretin cardiac amyloidosis and hypertensive heart disease","volume":"162","author":"Gallo-Fern\u00e1ndez","year":"2024","journal-title":"Med Clin (Barc)"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1578356\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T05:25:09Z","timestamp":1757481909000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1578356\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":15,"alternative-id":["10.3389\/fcvm.2025.1578356"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1578356","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]},"article-number":"1578356"}}